McKesson (MCK) has received a new Buy rating, initiated by William Blair analyst, Max Smock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Max Smock has given his Buy rating due to a combination of factors that highlight McKesson’s durable competitive position and earnings potential. He points to the company’s scale as North America’s largest pharmaceutical distributor, which positions it to benefit from favorable long-term trends such as an aging population, ongoing drug innovation, and faster growth in specialty medicines.
He also emphasizes McKesson’s expanding suite of technology and service offerings, which deepen customer relationships, raise switching costs, and create attractive new revenue streams beyond traditional distribution. Coupled with a strong balance sheet, solid free cash flow supporting buybacks, and an earnings outlook in the low- to mid-teens, he views the current 2026 valuation multiple as justified and maintains an unchanged price target of $828.
In another report released on April 22, UBS also assigned a Buy rating to the stock with a $1,000.00 price target.